Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.40 |
| ▸ | HTR3B | O95264 | 2/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.40 |
| ▸ | CHRNG | P07510 | 2/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17507688 | 0.96 | GAA (0.68) | GAAKMT2AEZH2CYP3A4LMNA | |
| SCHEMBL17507611 | 0.94 | GAA (0.64) | GAAKMT2AEZH2CYP3A4LMNA | |
| SCHEMBL17507728 | 0.92 | GAA (0.63) | GAAKMT2AEZH2CYP3A4LMNA | |
| SCHEMBL17522721 | 0.91 | GAA (0.61) | GAAKMT2AEZH2CYP3A4LMNA | |
| SCHEMBL17507717 | 0.90 | GAA (0.63) | GAAKMT2AEZH2CYP3A4LMNA | |
| SCHEMBL1556556 | 0.89 | GAA (0.74) | GAAKMT2AEZH2CYP3A4LMNA | |
| SCHEMBL29793926 | 0.89 | GAA (0.74) | GAAKMT2AEZH2CYP3A4LMNA | |
| SCHEMBL17522726 | 0.89 | GAA (0.66) | GAAKMT2AEZH2CYP3A4LMNA | |
| SCHEMBL17507712 | 0.87 | GAA (0.56) | GAAKMT2AEZH2CYP3A4LMNA | |
| SCHEMBL17522733 | 0.85 | GAA (0.54) | GAAKMT2AEZH2CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982731-B1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-9643924-B2 | Piperidine derivative, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9643924-B2 | Piperidine derivative, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20160039758-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039758-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2982731-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC Corporation (JP) | 2016-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039758-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, CCND1 | GAA 4581/4885KMT2A 1730/4885EZH2 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.